CD33-directed Immunoconjugate [EPC]

3665 reported adverse events

Drugs of this class: GEMTUZUMAB OZOGAMICIN

These side effects are most commonly reported by patients taking drugs of the CD33-directed Immunoconjugate [EPC] class:

# Side effect Count
0 FEBRILE NEUTROPENIA 698
1 PYREXIA 326
2 SEPSIS 302
3 VENOOCCLUSIVE LIVER DISEASE 260
4 THROMBOCYTOPENIA 240
5 PLATELET COUNT DECREASED 236
6 PNEUMONIA 197
7 NEUTROPENIA 194
8 WHITE BLOOD CELL COUNT DECREASED 185
9 ASPARTATE AMINOTRANSFERASE INCREASED 184
See all common reactions for CD33-directed Immunoconjugate [EPC]

Drugs of the CD33-directed Immunoconjugate [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 GRANULICATELLA INFECTION 11 0.2619
1 FIBRIN DEGRADATION PRODUCTS INCREASED 16 0.0541
2 VENOOCCLUSIVE LIVER DISEASE 260 0.0526
3 VENOOCCLUSIVE DISEASE 109 0.0435
4 CONGENITAL APLASIA 10 0.0322
5 LOWER RESPIRATORY TRACT INFECTION FUNGAL 12 0.0308
6 CENTRAL LINE INFECTION 9 0.0243
7 ACUTE MYELOID LEUKAEMIA RECURRENT 51 0.0237
8 ALPHA HAEMOLYTIC STREPTOCOCCAL INFECTION 20 0.0216
9 BLAST CELLS PRESENT 9 0.0187
See all enriched reactions for CD33-directed Immunoconjugate [EPC]